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1. Introduction
Juvenile Myoclonic Epilepsy (JME) was first described by Herpin [1] in the middle of the
19th century, reporting seizure symptoms he observed in his adolescent son. While Rabot
also described myoclonia in 1899 [2],  it  was not until  1957 when Janz and Christian [3]
provided a detailed explanation of the complete syndrome, which was subsequently called
by Antonio  Delgado-Escueta  [4]  as  “JME of  Janz”.  Since  then,  JME has  become a  well-
defined epilepsy syndrome that is recognized as one of the most common forms of genetic
generalized epilepsy (GGE). JME is primarily characterized by the hallmark manifestation
of myoclonic seizures (mainly upon awakening), although patients also often present with
a  combination  of  absence  and  generalized  tonic-clonic  seizures  (GTCS)  as  well.  Other
prevalent  features  of  JME  include  various  types  of  reflex  seizures,  particularly  with
photosensitivity. Electrophysiologically, there are prominent generalized ictal and interic‐
tal  discharges  on  scalp  electroencephalography  (EEG).  In  contrast  to  other  GGE  syn‐
dromes, such as Childhood Absence Epilepsy (CAE), and contrary to earlier assumptions,
JME has been shown to be associated with cognitive and behavioral problems, a lifetime
risk of continued seizures, and medication resistance.
In this chapter, we will review the electroclinical definition of JME along with treatments
for  its  associated seizure  types,  cognitive  and behavioral  complications,  and underlying
pathophysiology. In contrast to long-standing assumptions that JME is due to frontal lobe
hyperexcitability  that  primarily  involves  corticothalamic  pathways,  recent  literature
suggests that JME likely reflects an underlying developmental disorder affecting multiple
brain regions.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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2. Clinical definition
In an historical context, the syndrome has been previously referred to as “impulsive petit-mal”
epilepsy or Janz syndrome [5]. The International League Against Epilepsy (ILAE) later
designated the term “Juvenile Myoclonic Epilepsy” in 1975. Under the revised Classification
of Epilepsies and Epileptic Syndromes [6], the ILAE defined JME as follows:
Impulsive petit mal appears around puberty and is characterized by seizures with bilateral,
single or repetitive, arrhythmic, irregular myoclonic jerks, predominantly in the arms. Jerks
may cause some patients to fall suddenly. No disturbance of consciousness is noticeable. Often,
there are GTCS and, less often infrequent absences. The seizures usually occur shortly after
awakening and are often precipitated by sleep deprivation.
While the duration of myoclonic seizures are routinely short to the effect that it is often not
possible to determine if individuals lose awareness during episodes, repetitive or clustered
myoclonic seizures may be associated with altered levels of consciousness. Although GTCS
and/or absence seizures occur less frequently in JME, repetitive and clustered seizures can lead
to secondarily generalized tonic-clonic episodes. Whereas it is nearly pathognomonic for
seizures to occur upon awakening and are precipitated by sleep deprivation, an additional
diurnal pattern may also be apparent as myoclonic seizures can occur late in the afternoon or
in the evening as well. Electroclinically, interictal EEG patterns consist of generalized 4-6 Hz
spike-or polyspike-and-wave discharges, and a relatively high prevalence of photosensitivity.
3. Epidemiology
JME accounts for approximately 4-11% of all epilepsies [7-12] with an incidence of 0.1 to 0.2
occurrences in 100,000 per year. In terms of gender effects, early studies reported that the
incidence of JME was greater in male patients than females [13]; however, gender differences
have not been consistent across studies, as some studies [9] have shown an equal distribution,
and other researchers [10, 14-16] have reported a higher proportion (60%) of females. It is also
a typically occurring GGE [12], with prevalence in GGE groups ranging from 5.5% [17] to
representing the majority (45.5%) of patients [18]. Prevalence of JME as a proportion of GGE
may also differ across the lifespan in some individuals as approximately 15% patients with
childhood absence and juvenile absence syndromes develop JME as they age, especially those
patients with photosensitive spike-and-wave findings on EEG [4, 19]. As there is a strong
genetic component to JME, its prevalence is high among family members of JME patients as
well, which has been shown to be the case for certain ethnic groups. Studies from Saudi Arabia,
Turkey, and Iran have shown JME patients have a family association with rates that vary from
42.3 to 48.9% [18, 20, 21].
Not only are prevalence rates sensitive to genetic influences, the proportion of patients in
particular clinic settings may vary as well. For example, the prevalence in primary epilepsy
clinics is high, while it tends to be much lower in tertiary referral centers, due in large part
Epilepsy Topics78
because primary centers achieve successful treatment via antiepileptic medications. Moreover,
JME is often under-diagnosed and misdiagnosed [22, 23], which can present a challenge to
estimating its prevalence. As an illustration, a French study [24] showed that the prevalence
of JME in one geographic area was 0% between 1986 and 1994, which rose to nearly 50%
between 1996 and 2000, likely due to increased recognition of the syndrome. Moreover,
variations in clinical onset can present a challenge to estimating the prevalence of JME.
Although JME the peak age of onset is in adolescence (12-18 years), similar to most GGE
syndromes [10, 25], the age of onset can vary from 8 to 36 years. There are also de novo diagnoses
in early adulthood, and JME can, though rarely, begin or be reactivated in advanced ages. For
instance, a case report presented two patients from Turkey in whom JME began after the age
of 70 [26].
4. Clinical diagnosis
Myoclonic Seizures: As noted above, myoclonic movements are one of the main symptoms
of JME and consist of generalized seizures which are brief, irregular jerks of the head, trunk,
and limbs that can be either symmetric or asymmetric, and may involve isolated regions of the
body or the whole body. They usually predominate in the upper limbs (mostly distal muscles),
although they occasionally involve muscles in the abdomen, paraspinal distributions, and
lower extremity [27]. It is not uncommon for myoclonic seizures to be so subtle or brief that
they are perceived as benign “inner shocks”. As subtle as the may be, patients tend to more
readily notice asymmetric jerks involving the dominant upper extremity because such
movements noticeably impair daily functioning. The jerks, if violent, may cause the patient to
drop or throw objects, or fall to the floor-which may be mistaken for nonpathological clums‐
iness. Myoclonic seizures can manifest as discrete, single events or they may occur in clusters.
They are usually not associated with loss of consciousness but it is not uncommon for patients
to lose awareness during the jerks. Moreover, clusters of myoclonic events can evolve into a
GTCS and cause post-ictal confusion. They can occur during transition to sleep or during
awakening from sleep, usually in the early morning hours [28]. This early morning pattern of
seizures is associated with an increase in cortical excitability during that time of day, which
has been noted in other patients with GGE, but to a greater extent in JME patients [29].
Developmentally, these jerks often subside in the fourth decade of life, although GTCS or
absence seizures tend to persist [30].
Generalized Tonic-Clonic Seizures: About 80% of the patients with JME have GTCS. These
seizures are also more likely to occur if precipitated by sleep deprivation or alcohol intake.
Usually, these events are immediately preceded by a series of myoclonic jerks and associated
tongue biting prior to generalization. Because, as noted above, myoclonic events are often
insidious, patients first seek treatment following an initial GTCS and are then subsequently
diagnosed with JME. Typically, upon further evaluation, such patients acknowledge also that
they have experienced myoclonic jerks, a description which adds additional clinical support
for a JME diagnosis. Due to this association, some authors have proposed that clinicians should
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strongly consider a JME diagnosis, until proven otherwise, when teens present with an initial
unprovoked GTCS [31].
Absence Seizures: Absence seizures are characterized by a brief loss of awareness (i.e., a few
seconds) without any motor manifestations. Such seizures are relatively uncommon in patients
with JME. For example, Janz reported that 28% of his patients with JME had absence seizures
[3, 13]. Commonly, children who initially experience absence seizures may develop myoclonus
or GTCS within 1 to 9 years of their seizure onset, and then may subsequently be diagnosed
with JME. The absence seizures of JME differ from those of other GGE, such as CAE or Juvenile
Absence Epilepsy (JAE) as they are shorter in duration and associated with a lesser degree of
altered consciousness [32].
Myoclonic Status Epilepticus: Myoclonic status epilepticus is rare in JME and can present in
a variety of ways. Namely, patients can display prolonged myoclonic events, a combination
of myoclonic seizures and GTCS, or GTCS that that can follow prolonged absence seizures.
Risk factors for this clinical phenomenon include AED withdrawal, sleep deprivation, alcohol
intake, and suboptimal therapy [33, 34].
Precipitating Factors: As sleep deprivation is the usual precipitant of seizures in JME [35],
adolescents or a young adults often experience myoclonic or GTC seizures precipitated by late
night studying or socialization. Because of its strong association with precipitating seizures in
JME patients, sleep deprivation is typically employed as an activation procedure to provoke
characteristic EEG changes that are diagnostically relevant (4-6Hz generalized polyspike-and-
wave discharges). Also associated with sleep patterns, sudden and provoked awakenings,
pose additional increased risk for seizures in JME. Two-thirds of patients with JME have at
least one provoking factor [28].
5. Reflex seizures associated with JME
Reflex seizures are temporally preceded by some type of external stimuli and may occur
exclusively, or in conjunction with, spontaneous seizures. Common external triggers include
alcohol use, flashing lights, heat, bathing, and eating. They can also be less frequently elicited
by internal stimuli such as stress, fever, hyperventilation, thinking, fatigue, menstrual cycle,
and sleep. The proclivity of certain stimuli for seizure provocation is often age-dependent. For
instance, fever is a more common provoking stimulus in children than in adults.
Regardless of the suspected triggers, it is import to obtain a detailed history from patients and
family members to determine if there is a reflex component to seizures. This should include
querying about specific triggers, seizure semiology (partial or generalized), family history of
reflex seizures, and whether unprovoked seizures occur as well. As patients rarely lose
awareness with myoclonic seizures, they may have adequate awareness of their subjective
triggers. Knowing the patterns of responses in patients along with prevalence of triggers is,
therefore, key to initially investigating a reflex component prior to enlisting formal testing.
Moreover, identification of triggering factors leads to finding ways to avoid precipitants and
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develop nonpharmaceutical therapeutic interventions, which is important for the treatment of
reflex seizures, in addition to an AED regimen [36].
Using a questionnaire, da Silva Sousa [35] found 23% of JME patients surveyed reported having
reflex seizures with thinking and concentration, 20% with praxis, 11% with speaking in public,
15% with visual stimuli, 7% with reading, 5% with calculating and writing, 5% with music,
and 3% with drawing. In a subsequent study by the same group, patients were continuously
monitored for 4 to 6 hours by video-EEG while neuropsychological and physiological triggers
were presented [37]. These triggers had a provocative effect in 38%, with praxis being most
common trigger. There were also inhibitory effects of tasks in over 90%. 40% of the patients
had no effects on ictal or interictal epileptic discharges. A more recent multicenter, video-EEG
study, controlling for spontaneous fluctuation of ictal and interictal epileptic discharges, found
the provocative effect of neuropsychological and physiological triggers was decreased from
22 to 18%, while the rate of inhibition was decreased from over 90% to 29% [38]. The inhibition
was thought to be a non-specific effect of arousal and mental activation, while the provocative
triggers were task-specific.
In clinical practice, if reflex epilepsy is suspected from convergence of other clinical data as
noted above, clinical procedures can often helpful in identifying suspected triggers. Detailed
neuropsychological testing can be conducted with patients who have seizures induced by
thinking and completing complex mental activities [39]. Also, functional MRI can be used to
study signal changes in the networks involved in generating reflex seizures during tasks.
Because the prevalence of photosensitivity in JME ranges from 25 to 40% [40], clinicians often
opt to elicit reflex responses via intermittent photic stimulation (ILS) with concomitant routine
EEG with video. Photic stimulation typically consists of flashing light at various frequencies
in front of the patient, with seizures being most likely to be elicited by frequencies of 12-18Hz
in individuals who are photosensitive. Various visual patterns may be used to provoke
seizures as well, and include alternating, oscillating, black or white, or linear responses.
Beyond formal testing procedures via ILS, photoparoxysmal and convulsive responses along
with ictal and interictal epileptic discharges can be triggered by reading and praxis in patients
with JME [13, 40, 41]. Patients who are photosensitive may have the following responses: photic
driving, non-convulsive photoparoxysmal episodes, or photoconvulsive responses. Notably,
photosensitivity in JME patients is increased in the early morning hours soon after awakening,
which is consistent with the diurnal pattern of seizures in these patients [42]. There are no
differences in age or gender of patients with reflex seizures in general; however, in patients
with photosensitivity there is a clear predominance in adolescence and in the female sex [42].
In terms of the biological mechanisms of reflex seizures in JME patients, particular cerebral
regions have been implicated. Myoclonic seizures in JME are expressed in the primary motor
and supplementary motor cortices [43], which are extensively connected to the primary
sensory and association cortices. It is not clear whether visual stimuli generates a response
from the sensory cortices that propagates to functionally connected cortical and subcortical
structures, or if a there is parallel synchronization of larger networks induced by the stimuli
[44, 45]. In the case of photosensitivity, visual stimulation likely synchronizes frontoparietal
cortices prior to the onset of the epileptiform discharge [44-46], a phenomenon suspected on
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the basis of large cortical blood flow increases even before the appearance of hyperventilation-
induced generalized spike-and-wave discharges in absence epilepsy [47, 48]. Given the variety
of aforementioned triggers, it is expected that reflex seizures are provoked by stimulation of
different sensory cortices, such as the primary somatosensory cortex, primary auditory cortex,
or related association areas. For instance, somatosensory or cognitively evoked seizures are
evoked in physiologically activated cortical areas that overlap with hyperexcitable cortices
giving rise to ictal or interictal epileptic discharges [49].
6. Electrographic findings
Given the rate of reflex seizures in JME, it is clinically indicated to conduct a sleep-deprived
EEG with activation procedures, such as photic stimulation and hyperventilation. Although a
positive EEG highly supports a clinical diagnosis of JME, a negative EEG does not definitively
rule out the diagnosis. When examining EEG results, there are typical EEG patterns that occur
in JME that should be considered.
Interictal Pattern: The interictal background activity is usually considered normal in patients
with JME [4, 7, 50, 51]. However, Genton et al. [52] found that routine EEGs were normal in
27% of cases and misleading or nonspecific in 20% of cases; although, 54% showed generalized
interictal epileptic discharges (IEDs). Other studies have reported percentages of abnormali‐
ties, consisting of generalized polyspike-and-wave or spike-and-wave complexes in 75 to 85%
of probands [9, 53, 54]. The typical interictal EEG finding in JME is a 3.5-6 Hz spike-and
polyspike-and-wave pattern with a frontocentral predominance that lasts up to 15 to 20
seconds [50, 55]. While a pattern of more prolonged IEDs with a 2-3 Hz frequency is not specific
to patients with absence seizures, there may be an increased risk of clinical absence seizures if
a 3Hz spike-and-wave interictal pattern is noted. IEDs are primarily detected during drowsi‐
ness and or sleep onset, or upon awakening [56, 57] (see Figures 1-3), during ILS (photopar‐
oxysmal response) (see Figure 4), and hyperventilation. They may be associated with
myoclonic seizures or GTCS (photoconvulsive response). Family members of JME are often
affected or carry the abnormal EEG traits, as 80% percent of symptomatic siblings and 6% of
asymptomatic siblings have diffuse 4-6 Hz spike-and-wave complexes [58]. Photoparoxysmal
EEG response is another heritable trait of JME, and can be found in 20 to 60% of near relatives
of probands [59].
Ictal Pattern: The ictal EEG during myoclonic jerks (see Figure 5) typically reveals a sudden
onset of brief (less than 0.5 sec) bursts of 10-16 Hz polyspike-and-wave discharges often
followed by 1-3 Hz slow waves [60]. The number of spike-and-wave complexes ranges from
5 to 20 per discharge and correlates with the intensity,  rather than the duration of each
seizure [3]. Absence seizures in patients with JME are usually associated with 3 Hz spike-
and-wave activity, which is sometimes preceded by 4-6 Hz polyspike-and-wave discharg‐
es that decrease in frequency to 3 Hz as the patient loses consciousness. These spike-and-
wave  discharges  are  usually  shorter  in  duration  than  those  observed  in  childhood and
juvenile absence epilepsies [61].
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Legend: The discharge is originally 5 Hz, slowing down to 3 Hz. No clinical signs were noted.
Figure 1. Generalized Interictal Epileptic Discharge in Drowsiness
Figure 2. Generalized Polyspikes Activated in Stage II Sleep
Juvenile Myoclonic Epilepsy — A Maturation Syndrome Coming of Age
http://dx.doi.org/10.5772/58372
83
Figure 3. Fragmented Spikes in Slow-Wave Sleep
Figure 4. Photoparoxysmal Response
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Legend: Note movement artifact on ECG channel.
Figure 5. Myoclonic Seizure
7. Focal features of EEG
Accurate identification of EEG patterns is crucial to avoid misdiagnosis of JME (e.g., misiden‐
tified as a partial seizure). As an illustration, some researchers have reported that clinical and
EEG asymmetries can lead to a delay in the diagnosis of JME by an average of 2 years [62].
Thus, it is important to understand that although JME is classified as a GGE, myoclonic seizures
and GTCS may be associated with a combination of focal clinical and/or EEG findings.
However, focal abnormalities are rarely found on routine neurological exams or MRI studies.
Further, the challenges of making a diagnoses by electroclinical data is best exemplified by
evidence of versive seizures or circling seizures that are associated with generalized discharges
on EEG [63, 64].
Data from JME patients in the UK found that 36.7% of EEGs had focal slow waves, spikes, and
sharp waves as well as focal onset of a generalized discharge. In more than half of the JME
patients, at least one EEG showed focal abnormalities [65]. 18 patients with JME were studied
in Poland which demonstrated that 8 patients had focal abnormalities on EEG that previously
led to misdiagnosis [66]. Further, a large study of JME patients in India [67] found asymmetrical
clinical presentations in 17% of patients and focal EEG abnormalities were seen over 45% of
patients. Of these patients, focal findings seen on EEG included amplitude asymmetry or a
lateralized onset of generalized discharges in 45% and independent focal EEG abnormalities
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in 33% of patients. A video-EEG study from the Cleveland Clinic Foundation [68] reported
that of the patients with only JME, 54% exhibited either focal semiologic or electroencephalo‐
graphic features or a combination thereof. Focal myoclonic seizures (i.e., unilateral myoclonic
jerks, version, and asymmetric limb posturing) were recorded in six patients whose ictal EEG
showed a generalized seizure pattern. Two patients had lateralized upper extremity extensor
posturing (“sign of four”) with evolution of a GTCS. They also reported that one patient had
primary GTCS presenting after successful resection of a parietal tumor, and two patients had
temporal lobe epilepsy in addition to JME. Taken together, the findings of focal or multifocal
clinical or EEG abnormalities suggest the possibility of a symptomatic etiology, and may reflect
an underlying genetically mediated neurodevelopmental disorder.
It has also been suggested that asymmetric EEG findings in such patients increase the proba‐
bility of decreased response to standard antiepileptic therapies. A group of Canadian re‐
searchers [69] presented data showing 90% of their JME patients had generalized epileptiform
discharges on EEG and 57% of patients had asymmetric EEG abnormalities, including focal
epileptic discharges or slowing. Of their patients, over 39% were medically refractory to at
least one AED, and a poor treatment response was observed to a greater degree in patients
with EEG asymmetries. Nevertheless, the clinical significance of focal clinical or EEG abnor‐
malities has not received much attention in the literature.
8. Differential diagnosis
Doose Syndrome: Myoclonic-astatic epilepsy was first described by Dr. Hermann Doose in
1970 [70]. The ILAE classified it formally as symptomatic generalized epilepsy, and it was
renamed as epilepsy with myoclonic-atonic seizures. It is much less prevalent than JME (1 to
2% of all epilepsies) and has a younger onset age (7 months to 6 years, peak of 2 to 4 years)
with a greater prevalence among males. Unlike JME, there is an association with cognitive
impairment, which is severe in some cases of Doose Syndrome. This syndrome is characterized
by symmetric myoclonic jerks followed by sudden atonia. During a myoclonic atonic seizure,
the EEG consists of irregular generalized 2-3Hz or more spike-and polyspike-and-wave
discharges. The atonic seizures coincide with subsequent slow waves. The interictal EEG
background similarly consists of frequent 2-3 Hz generalized spike-and polyspike-and-wave
discharges, contrasted 4-6 Hz discharges in JME. Up to 50% of patients may achieve seizure
freedom and continue to have normal development, but the remainder may have severe
impairments in cognitive functioning, behavioral problems, and ataxia [71].
Childhood Absence Epilepsy (CAE): CAE is a type of GGE that has an age of onset of 4 to 10
years with a peak between 5 to 7 years [72]. The characteristic seizure type is an absence seizure
during which there is brief loss of consciousness for a few seconds with associated behavioral
arrest, eyelid myoclonia, and rare hand and facial automatisms [73]. They may occur multiple
times a day. While absence seizures may also occur in JME, their frequency and duration is far
less than in CAE. The interictal EEG of CAE is characterized generalized spike-and polyspike-
and-wave discharges of 3Hz frequency [6]. Prognosis for CAE is considered excellent, with
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possibility of remission upon discontinuation of antiepileptic medications. In patients with
CAE, the development of GTCS or myoclonic seizures may indicate a poorer prognosis, and
increases the probability that such patients will develop JME.
Juvenile Absence Epilepsy (JAE): Similar to JME, JAE is a GGE that mainly presents during
adolescence, usually at the age of 10 to 17 years. Although the central semiology is signified
by absence seizures, there is often less impairment of consciousness than in CAE, and the
seizures do not tend to occur in clusters. On the other hand, GTCS seizures are more common
(reported in 80% of patients) with JAE, similar to JME. While some authors have contended
that myoclonic jerks do not occur in JAE [32], the ILAE has included them in the definition of
JAE [6]. As such, 15 to 25% of JAE patients have myoclonic jerks-they are infrequent, mild, and
of random temporal distribution [74]. In comparison to JME, myoclonic movements usually
occur in the afternoon rather than in the morning after awakening.
Myoclonic Absence: This rare epilepsy syndrome begins in preadolescence and is character‐
ized by prolonged absence seizures lasting 10-60 seconds in duration with rhythmical bilateral
myoclonias affecting the extremities, often synchronously with 3 Hz polyspike-and-wave
discharges [75]. This syndrome is associated with cognitive dysfunction and is medically
refractory in a majority of the patients.
Generalized Tonic-Clonic Seizures Upon Awakening: The onset of this epilepsy syndrome
is also in adolescence [6]. As in JME, the GTCS tend to occur upon awakening. There is still
debate on whether this syndrome should be classified with JME, due to electroclinical
similarities and possible genetic associations [76]. However, patients with GTCS Upon
Awakening do not exhibit myoclonic or absence seizures.
Progressive Myoclonic Epilepsy (PME): Progressive myoclonic epilepsies are a group of
genetic disorders which are characterized by myoclonus, seizures, and advancing cognitive
and neurological decline [77]. Examples of PMEs include Lafora disease, neuronal ceroid
lipofuscinosis, Unverricht Lundborg disease, myoclonic epilepsy with ragged red fibers
(MERRF), Gaucher disease, and dentatorubral pallidoluysian atrophy. They can start in
childhood, adolescence, or young adulthood and tend to be associated with multiple neuro‐
logical and cognitive deficits. The myoclonus associated with these disorders can be induced
by action or stimulation and tends to be multifocal. ILS tends to activate myoclonus at
frequencies below 6 Hz. These diseases are associated with progressive neurological deterio‐
ration along with worsening seizure control. The diagnosis is more difficult to determine,
primarily during the early stages of the disease when seizure severity is limited [78].
9. Treatment of JME
Response to treatment is drug-specific in the case of JME. Valproic acid (VPA) is considered
the first line of therapy in patients with GGE, especially JME; however, it is not FDA approved
for this condition [79, 80]. Rather than randomized control trials, evidence supporting the
choice of VPA has primarily come from observational studies. While VPA is a broad spectrum
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antiepileptic medication, it is very effective in 80% of patients [81]. Nonetheless, even in
seizure-free patients, discontinuation of VPA leads to a very high rate of relapses [9]. A chart
review from Duke University [82] of 33 JME patients identified resistance to VPA in 30%. The
VPA refractory patients had a higher prevalence of EEG asymmetries (40% vs. 10%), atypical
seizure characteristics including auras and postictal confusion (30% vs. 4%), and intellectual
deficiency (20% vs. 0%). Clinical characteristics combined with EEG data may help in predict‐
ing which JME patients will respond favorably to VPA.
More recent support of VPA’s relative efficacy over other antiepileptic medications was
demonstrated The Standard and New Anti-Epileptic Drugs trials (SANAD) [83]. SANAD was
a concurrent pragmatic parallel group, open-label, randomized trial which examined seizure
control, tolerability, quality of life, and economic outcomes of standard antiepileptic medica‐
tions used for GGE. VPA was compared with lamotrigine (LTG) and topiramate (TPM), and
was significantly better for time to treatment failure (i.e., seizure control, side effects, addition
of another AED). For time to 12-month remission, VPA was significantly better than LTG for
GGE. Overall, VPA was better tolerated than TPM and more efficacious than LTG. In children
with GGE, a retrospective observational study [84] examined the long-term effectiveness of
LTG compared to VPA monotherapy in newly diagnosed patients. After 12 months of
treatment, 69% patients continued LTG compared to 89% that adhered to their VPA regimen;
after 24 months rates were 57% and 83%, respectively. Valproate showed equal efficacy in all
GGE syndromes, whereas LTG showed better efficacy in CAE and JAE syndromes, than in
JME.
Although VPA can be used safely by a number of patients, including those with comorbid
psychiatric disease or underlying psychiatric vulnerability [85], there are some limitations. In
particular, there is a high risk of teratogenicity as well as delayed cognitive development in
children (pregnancy class D) [86, 87]. Exposure to VPA in utero has been associated with
maladaptive behavior and decreased socialization skills in childhood [88, 89] as well. In cases
where VPA is used during pregnancy, either because of unplanned pregnancy or because
alternative treatment options of equivalent efficacy are unavailable, appropriate counseling,
precautionary measures, and monitoring should be provided. Although LTG may have a lower
efficacy, and has even been reported to increase myoclonic seizures in some patients, it is a
popular alternative to VPA in women in childbearing age for the treatment of JME.
LTG and TPM have FDA approval for primary GTCS in the United States. Hence, more studies,
albeit with small numbers of participants, have been conducted with those agents. An open-
label study [90], designed to evaluate LTG monotherapy as a possible alternative in patients
with JME who previously failed VPA, found LTG to be as effective and better tolerated
compared with VPA. A small (N=28) randomized, controlled trial [91] compared TPM and
VPA in adolescents and adults during a 12-week maintenance period, which resulted in 67%
seizure freedom in the TPM group and 57% in the VPA group. The researchers concluded that
TPM may be an effective, well-tolerated alternative to VPA as the groups had similar rates of
adverse effects. Similarly, a prospective, open-label, randomized observational study in Korea
[92] compared the efficacy and tolerability between TPM and VPA in patients with JME and
did not find differences in efficacy, although the side effect profile of TPM was more favorable.
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Clonazepam (CLN) was one of the first medications to be approved for myoclonic seizures
and GTCS. While VPA is as an effective treatment for most patients with JME, one study
showed [9] additional efficacy with CLN adjunctive therapy to control myoclonic seizures.
However, CLN monotherapy did not consistently prevent GTCS. The authors concluded that
adding CLN may allow the dose of VPA to be reduced in patients demonstrating dose-
dependent VPA side effects. The addition of CLN can also be utilized in combination with
other antiepileptic medications as well.
Levetiracetam (LVT) was more recently approved for the treatment of myoclonic seizures
associated with JME. Similar to CLN, it can reduce the myoclonic seizures and GTCS [93],
possibly with even better long-term efficacy and fewer side effects. Recently, several studies
found LVT to be effective in all  types of seizures in JME as concluded in a randomized
double-blinded placebo controlled trial [94, 95]. Hence, LVT is another worthy alternative
to VPA, especially in women of  childbearing age.  Other medications that  may be effec‐
tive  in  JME include  zonisamide  (ZNS),  felbamate  (FBM),  lacosamide  (LCM),  and cloba‐
zam  (CLB);  however,  systematic  trials  of  those  medications  are  lacking.  Nonetheless,  a
retrospective chart  review demonstrated that  ZNS monotherapy was effective and well-
tolerated in JME patients [96].
In contrast to effective AED treatments, there are a number of antiepileptic medications that
may aggravate certain seizure types associated with JME, particularly myoclonic and absence
seizures. Among commonly prescribed anticonvulsants, carbamazepine appears to have the
strongest aggravating potential for myoclonic seizures, whereas the aggravating effect of
phenytoin (PHT) is less prominent [97]. A retrospective study of patients with GGE, showed
that oxcarbazepine (OXC) also aggravated myoclonic and absence seizures, and increased
interictal epileptic discharges on EEG [98]. A retrospective study of adult GGE patients who
developed video-EEG documented status epilepticus were all found to be taking either CBZ,
PHT, vigabatrin (VGB), or gabapentin (GBP). Potential precipitating factors included dose
increase of CBZ or PHT, or the initiation of CBZ, VGB, or GBP, as well as a decrease of
phenobarbital (PB) dosage. Withdrawal of the aggravating agents and adjustment to medica‐
tion resulted in full seizure control in that study. Therefore, it is important to make the
appropriate diagnosis and medication selection to avoid potentially worsening certain seizure
types. It is also important to consider the age, gender, comorbid conditions, and drug inter‐
actions when initiating antiepileptic therapy in JME patients.
10. Lifestyle modifications
As with a number of other chronic medical conditions (i.e., diabetes, hypertension, obesity),
lifestyle factors have an important role to play in managing epilepsy disease burden. To
illustrate the problems of how psychosocial factors influence the treatment of JME, Baykan
et al. [30] followed 48 patients with JME for a mean of 20 years and found that 16.7% of
patients  had  “pseudo-resistance”  due  to  medication  non-adherence  and lifestyle  related
issues. Sharpe and Buchanan [99] studied 36 patients with JME at a tertiary referral hospital
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and found that most patients with poor seizure control had provoked seizures only, which
prompted the authors to emphasize the importance of lifestyle changes in managing seizures
in JME.
Thus, perhaps the most obvious lifestyle factors worth noting in terms of JME pertain to
patients’ exposure to stimuli s associated with increased seizure frequency (i.e., fatigue, stress,
sleep deprivation, alcohol intake, drug use, photic stimulation, stress, AED withdrawal/non-
compliance) [9, 100-103]. From a disease management perspective, behavioral medicine
strategies that are promoted by integrated, multidisciplinary teams may prove useful [104].
Elements of such programs often include steps to improve medication adherence, treat
psychological problems and manage stress, implement sleep hygiene interventions, and
develop methods to cope with exposure to possible seizure triggers [104-106]. Moreover,
administration of psychoeducation should be considered a minimum standard of care by
providing patients with information regarding identifiable triggers, risks of sleep deprivation,
possible problems with exposure to stroboscopic flashes, relationship of alcohol intake and
seizure control, as well as ways to increase AED adherence to prevent further seizures [107].
Although, some authors [103] have suggested that it is more efficient to use higher doses of
AEDs in the initial treatment of JME, rather than implement behavior change strategies,
systematic study of the effects of multidisciplinary treatment on lifestyle factors in epilepsy
has remained an understudied area. However, initial studies in JME have suggested that there
may be a desirable effect on seizure control, and likely improvements in quality of life. If some
of these measures are put into place, it is likely that the number of patients with refractory
seizures will be reduced [108, 109].
11. Cognitive and behavioral tasks
There have been studies suggesting that cognitive tasks can provoke or inhibit of epileptiform
discharges in patients with JME [110]. These uncommon precipitating factors, such as mental
and motor hand tasks, may be under-recognized in JME [35]. A Japanese study involving 480
patients with epilepsy tested the effect of cognitive tasks on EEG (i.e., neuropsychological EEG
activation) consisting of reading, speaking, writing, written calculation, mental calculation,
and spatial construction. They found that these cognitive tasks have an inhibitory effect on
EEG discharges in the majority of epilepsy patients (64%), although they have a provocative
effect in other patients (8%). The seizures caused by the provocative effect of these tasks were
found to be precipitated by action programming or thinking activity (linguistic and praxic)
[111]. Following this, Beniczky et al. [38] studied 60 patients with JME and found that the
provocative effect of the cognitive tasks is task-specific, whereas the inhibitory effect seems to
be related to cognitive activation in general. Another study involving 76 JME patients had
similar results, suggesting that the inhibitory effect of these tasks support non-pharmacologic
therapeutic interventions in JME [37].
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12. Non-medical treatments
Alternative surgical therapies do not represent standard of care and are not approved for JME.
However, in medically-refractory patients, clinicians often employ additional treatment
options.
Vagal Nerve Stimulator: While vagal nerve stimulators (VNS) are approved for the treatment
of medically refractory partial seizures, its use in JME has not been well documented. None‐
theless, the most recent AAN guidelines on VNS for epilepsy [112] asserted that VNS was
effective in children with medically-refractory GGE. A greater than 50% reduction in seizure
frequency was reported in 55% of the 470 children with partial or generalized epilepsy in the
reviewed literature (13 class III studies). Based on those findings, the authors concluded that
VNS could be considered adjunctive treatment. No such recommendations have been made
regarding adult treatment as more trials are needed in that population.
One of the few JME specific studies of VNS [113] indicated that adjunctive therapy with VNS
might be considered a favorable option for treatment of refractory cases of GGE, and may be
the only alternative to refractory JME. A total of 12 cases with GGE and VNS implantation
were followed for a mean of 23 months. It was found that the rate of seizure total reduction
was 61%: a 62% reduction of GTCS, 58% reduction in absences, and 40% reduction of myoclonic
seizures. Five of the seven patients in that study who had a JME diagnoses were responders,
two of which became seizure free. One patient in that study was diagnosed with JME and failed
conventional treatment that included 8 AEDs and the ketogenic diet. Subsequent to VNS
implantation, she had >75% reduction in GTCS along with >50% reduction in absence and
myoclonic seizures.
Corpus Callosotomy: There are even fewer studies that have examined the effectiveness of
corpus callosotomy for medically refractory cases of JME. A case series (N=11) from Brazil
[114] included GGE patients who underwent extensive one-stage callosal transections. At least
75% reduction in frequency of GTCS was noted in all patients; three patients had complete
remission of absences and the other patients had a >90% reduction in the frequency of absence
seizures. Only one patient who had myoclonic seizures prior to surgery remitted completely
after surgery. Postoperative EEG recordings showed disruption of bilateral synchrony of
interictal epileptic discharges in all patients, with minimal neurological deficits. While the
authors reported that the patients only showed a decline of 4 points in mean FSIQ standard
score, a more detailed examination of the patients’ psychosocial status and cognitive func‐
tioning was not reported. A Japanese case report [115] of medically refractory JME showed
that an anterior corpus callosotomy resulted in a desynchronization of generalized spike-and-
wave discharges and a complete resolution of myoclonic seizures. An anterior corpus callos‐
otomy may be effective for seizure reduction in some cases of refractory GGE due to the
disruption of interhemispheric synchronization [116].
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13. Prognosis
As with most GGE syndromes, JME responds well to an appropriate AED regimen, demon‐
strating a 70 to 80% response rate [117]. However, the long-term prognosis remains AED-
dependent as there is an 80% recurrence risk after AED withdrawal. It is thought that CAE
typically has a better prognosis and spontaneous remission that JME even when untreated,
although this can be complicated by the development of myoclonus. In fact, a Canadian study
[19] noted that 65% of children with CAE experienced remission after 10 to 18 years after their
diagnosis, although 44% of patients who did not experience remission developed JME.
A long-term population-based study [14] that included 24 patients (majority women) who
developed JME by 16 years of age were followed for up to 25 years after seizure onset. Eight
patients (36%) developed convulsive status epilepticus and three patients (12.5%) had
intractable seizures. In this cohort, 17% of patients had full remission of all seizure types and
only myoclonic seizures persisted in 13%. Thus, about one-third of patients had remission of
disabling seizures without the need for continuation of AEDs. Moreover, although JME rarely
undergoes spontaneous remission, there may be an age effect that increases the probability of
spontaneous remission as individuals reach the fourth decade of life. In another long-term
study [30, 118] that followed 48 patients with JME (mean age of 40 years) for approximately
20 years, the authors indicated that seizure severity and myoclonic frequency seemed to
change across the lifespan. For instance, myoclonia went into remission in the fifth decade of
life in 54% of patients. Five patients discontinued AED treatment and six patients had lower
AED dosage; 10 out of 11 of these patients did not relapse during the mean follow up of 8 years.
One of the longest outcome studies of JME [119] followed 31 patients for an average of 39 years.
Over two-thirds became seizure free, a third of whom could be taken off AEDs altogether.
Predictors of poor outcome were identified as presence of GTCS preceded by myoclonic
seizures, longer duration of epilepsy, and the need for AED polytherapy. Predictors of seizure
freedom included complete control of GTCS. Other factors may also influence remission as
well. In a study of 32 JME patients in Japan, those with focal interictal epileptic discharges on
EEG and or discharges activated by cognitive stimuli, had the least favorable outcome [120].
However, value of EEG in predicting outcome of JME remains controversial [121]. A study
from Brazil [122] showed that patients with persistent seizures had an earlier age of onset,
higher prevalence of personality disorders, and higher incidence of sensitivity to praxis-and
verbally-induced ictal or interictal epileptic discharges.
Hence, it appears that a subgroup of patients can be identified as being at a higher risk of
refractory seizures. JME patients with an earlier onset of epilepsy, GTCS evolving after a build-
up of myoclonic seizures, focal EEG abnormalities or sensitivity to cognitive activation, and
cognitive or behavioral problems may be more likely to remain refractory to antiepileptic
medications. Ideally, the significance of these factors needs to be validated prospectively by a
multicenter, multinational study.
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14. Cognitive dysfunction
Consideration of neuropsychological findings in JME has a brief history beginning with largely
anecdotal reports suggesting patients displayed a combination of behaviors consistent with a
“frontal syndrome” [3] in the context of normal intellectual functioning. As the following
literature illustrates, the initial assertions that JME patients display a unitary “frontal syn‐
drome” are challenged by data from a number of novel empirical designs. For instance,
consideration of non-frontal factors is considered germane in light of the involvement of
multiple brain regions that extend beyond structural frontal anatomy in JME [123]. Several
themes of investigation have surfaced regarding cognition including delineation of neuropsy‐
chological profiles in JME, group performance differences, disease specific and non-disease
factors that may affect cognitive functioning, along with neuroanatomical and functional
correlates of task performance. Because of the idiopathic nature of JME and its strong genetic
linkage, family studies of cognition have surfaced as well.
Given that JME has been conceptualized as a disorder affecting frontal brain regions, some of
the first empirically-driven studies focused on the relationship of JME and performance on
tasks that theoretically require significant frontal lobe recruitment. In this vein, JME groups
have been assessed by a number of clinical and basic research cognitive measures that task
frontal systems. For instance, a small study showed that a group of adult JME patients (n=9)
demonstrated an abnormal number of errors and omissions on a task that requires individuals
to identify previously learned complex visual information [124]. Such match-to-sample
measures often have immediate and delayed portions that task visual working memory
systems, which an aspect of executive functioning. The magnitude of abnormality was
generally not as large as performance by a group of patients with frontal lobe epilepsy (FLE;
n=15), although it was typically lower than control participants’ (n=14) proficiency. In a follow-
up study with a similar task, researchers from that group [125] reported that adult JME patients
(n=9) had fewer correct responses than controls (n=14) on the same delayed match to sample
paradigm. The JME patients performed normally on the immediate match to sample tasks,
which generally relates to attentional functioning, but slower psychomotor speed performance
than controls. However, it is not clear if the same patient and control groups were used across
both of the studies, which decreases the generalizability of the findings. Nevertheless, these
two projects served as stringboards for subsequent applied and experimental designs.
While it is important that the latter studies showed commonalities between theoretically
similar patient groups (i.e., groups with suspected frontal lobe abnormalities) in order to
provide additional validity evidence for a “frontal” construct, it is also relevant to include data
from groups that are theoretically divergent (i.e., controls, various non-frontal clinical
samples). As such, neurocognitive performance of a mixed sample [126] of patients diagnosed
with temporal lobe epilepsy (TLE; n=15) and JME (n=15) was contrasted on a number of tasks
related to frontal lobe functions. JME patients had impairments on a wide range of cognitive
measures, as defined as >1.5 standard deviations below the mean for the normative comparison
group. Of the 15 JME patients used in their analyses, one patient showed no impairment on
testing, while half of the remaining sample had impairments on <3 tests and the other half was
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impaired on >4 tests. Performance was most frequently impaired on a task that requires one
to identify relationships between objects on a conceptual level, which was significantly
discrepant from the TLE group. Additionally, patients were administered a task that requires
individuals to quickly and sequentially alternate responses according to specific rules (i.e.,
Trailmaking Test Part B). On this task, the JME participants had lower scores than the TLE
patients.
Additional studies have contrasted JME groups on test batteries that primarily include
executive function tasks that have a relationship with frontal lobe involvement. Piazzini et al.
[127] reported data from an adult sample of patients with JME (n=50), TLE (n=40), FLE (n=40),
and controls (n=40). In that study, JME patients performed statistically significantly lower than
TLE patients and controls, yet scored similarly to FLE on the Wisconsin Card Sorting Test and
a semantic verbal fluency test. A group in Austria [128] published data from two studies [129,
130] that included a decision-making task and a number of neuropsychological variables in
patients. Their results showed that JME patients performed similarly to mesial TLE patients
on nearly all variables except they had lower semantic verbal fluency scores and slower
psychomotor speed. The groups were otherwise similar on measures of verbal attention, verbal
working memory, cognitive flexibility, planning, along with abstraction and categorization.
Other results [131] indicated that children with CAE (n=28), another GGE, largely performed
worse than individuals with JME (n=11) on tasks of visual sustained attention, the Stroop Test,
and Trailmaking Test. No differences were noted for verbal memory. Another group [132]
sampled children and adolescents who had a similar level of normal intellectual functioning
and were diagnosed with either recent-onset JME (n=20) or recent-onset benign childhood
epilepsy with centrotemporal spikes (BCECTS; n=12). A sample of first-degree cousins (n=51)
were also utilized as control participants. The researchers focused their cognitive assessment
on objective measures of executive functioning that included subtests from the Delis-Kaplan
Executive Function System (D-KEFS). They also examined behaviors that were subjectively
rated by parents on the Behavior Rating Inventory of Executive Function (BRIEF). In their
samples, the JME group performed significantly poorer than the control group on the D-KEFS
Inhibition subtest. Parent report on the BRIEF indicated the JME group had more pathological
ratings on the Behavioral Regulation and Metacognition scales than controls as well. However,
there were no significant differences between the BCECTS and JME group on any measures.
The latter study highlights that executive differences exist early in the disease course of JME,
although the magnitude of executive dysfunction may not be larger than that in other genetic
epilepsies.
There have also been reports [133] of cognitive functioning in mixed samples of children and
adolescents with normal intellectual functioning diagnosed with GGE (i.e., JME & Absence)
and genetic localization-related epilepsies (i.e., BECTS & non-BECTS). Although that study
included 26 JME patients and a number of other patients with IPE, the JME group was
compared only with the 72 healthy children, which indicated that the JME group performed
below the mean of the control group in all cognitive domains (e.g., intelligence, academic,
language, memory, executive functioning, fine motor dexterity and speed, cognitive process‐
ing speed). In particular, JME patients’ lowest performance was in arithmetic, inhibition,
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concept formation, psychomotor speed, and fine motor dexterity and speed. While visual
inspection of the data suggested that JME patients performed lower than the group with
absence seizures on a measure of language fluency, the group with absence seizures appeared
to perform lower in all other domains. However, statistical group comparisons were not
conducted to differentiate any of the clinical groups from one another.
Just as there has been variability in finding group differences between patient samples,
findings from studies contrasting JME patients from healthy controls have been mixed and
contradictory. In addition to the few clinical comparison group designs noted above, a number
of other studies have shown that JME patients have statistically significantly lower proficiency
than controls across a host of measures including intelligence [134, 135], verbal IQ [135],
working memory [135], digit span [136-139], sustained attention [134], processing speed [134,
135], Trailmaking Parts A and B [137-139], Trailmaking Part B [140], mental flexibility [134,
137, 141, 142], response inhibition [134, 143], Stroop Test [137, 139, 140], Stroop Interference
[136], speeded color reading [143], verbal abstraction [141], concept formation [136, 137, 142],
perseverations[140], clock and cube drawing [143], sematic fluency [136, 138, 140, 143-145],
phonemic fluency [137, 138, 140, 141, 144, 145], naming [135, 141], verbal learning and memory
[138, 140, 143], visual memory [140, 141], and prospective memory [136]. On the other hand,
a number of studies have also failed to find group differences on tasks of IQ [138, 143, 144],
verbal intelligence [141, 145], auditory working memory and attention span [141, 143-146],
spatial span [144, 145], spatial working memory [147], psychomotor speed [146], motor speed
[134], mental flexibility [146], Trailmaking Parts A and B [145], response inhibition[141, 144,
145], figural fluency [134, 145], semantic fluency [141, 146], phonemic fluency [146], reading
[134], naming [143], language comprehension[144], line orientation [143], facial recognition
[143], memory [134], verbal learning [141, 144, 145], visual memory [144, 145], and design
learning [141]. Another more recent study [148] reported no difference between JME patients
and controls on a range of neuropsychological measures. Beyond functioning on objective
cognitive tasks, another avenue for research is to examine patients’ perceptions of cognitive
dysfunction. Such a design has shown the JME patients rate a higher level of self-reported
executive dysfunction than controls [144].
Given that the variability in findings across studies likely relates to a number of primary and
secondary factors, the influence of the effects of such factors is also likely varied. For instance,
one small study [128] showed that it may be important to consider the influence of seizure
frequency on JME patients’ abilities. In general, the JME patients in their sample did not
perform differently from healthy controls on tasks of verbal attention, verbal working memory,
or phonemic verbal fluency. On the other hand, controls consistently performed higher than
JME patients on tasks related to psychomotor speed, cognitive flexibility, categorical verbal
fluency, planning, along with abstraction and categorization. The patients who had been
seizure free (n=11) for a year were also compared with patients who continued to have seizures
(n=11). The groups showed no differences on any of the cognitive testing, although JME
patients scored significantly lower on three of four indices of a decision-making task than
controls; seizure status in the JME group was related to performance. However, when
compared with controls, the patients who were not seizure-free also showed additional
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significant differences on measures of cognitive flexibility, planning, and facets of a decision-
making task than the seizure-free patients. Another study [146] examining performance on the
same decision-making task reported no difference between controls and JME patients as a
group, although fewer patients who were not seizure-free showed improvement and learning
on the task over time. These findings suggest that seizure frequency may be an important
modulator of cognitive abilities in JME patients.
Overall ability level, such as intelligence, has been shown to relate to performance across
cognitive domains [149, 150]. This is likely to be the case with JME patients as well and may
influence the significance level of research findings, particularly in small samples. As an
example, heterogeneous cognitive performance in JME patients was noted in a published
abstract [151], indicating that drug-resistant patients who performed in the impaired range on
tasks of executive functioning had a high rate of impairments on tests in other domains.
However, there were only limited published data available to review from that report. Other
variables have been associated with cognitive performance in JME patients as well such as age
of epilepsy onset [138], duration of epilepsy [135, 138], and educational level [135]. Addition‐
ally, JME patients on a regimen of multiple AEDs may perform worse than patients on
monotherapy on tests of psychomotor speed, cognitive flexibility, and phonemic fluency [128].
On the other hand, some studies have shown no relationship with cognitive performance in
JME groups related to duration of epilepsy [127], education level [138], the frequency of
seizures [127, 138], treatment status [127], the type of seizures [127], age [138], sex [138], family
history [138], or previous intake of an AED [138].
In addition to demography, there may be biological determinants of particular cognitive
performance profiles in JME. In a magnetic resonance spectroscopy (MRS) study of the brain
[152], researchers indicated JME patients with reduced frontal N-Acetylaspartic acid had lower
mental flexibility compared with JME patients with normal levels. Other biological influences
may relate to cognitive functioning as well. In JME patients, frontal and thalamic volumes have
been associated with executive task performance [132]. Those researchers did not show similar
anatomical relationships with cognitive performance in patients diagnosed with other
epilepsies [132]. Similar work [141] has revealed an association of fractional anisotropy (FA),
a measure of white matter integrity on diffusion tensor imaging (DTI), in anterior supplemen‐
tary motor area (SMA) regions with scores on a picture naming task. FA values in the posterior
cingulate region and corresponding gray matter volume (GMV) negatively predicted scores
on the Trailmaking task. However, no other FA values were correlated with any other clinical
variables or neuropsychological testing scores [141]. In terms of functional paradigms, fMRI
patterns have differed for JME patients versus controls during tasks that require a high level
of attention, concentration, and working memory, suggesting motor cortex involvement even
though there were no group differences in the actual outcome of the task [147]. This suggests
that there may be alterations in or pathological changes to cerebral regional recruitment during
task performances as a function of disease state.
Regarding EEG studies, mixed findings have been demonstrated for the relationship of EEG
patterns on cognitive performance. One group [143] examined the influence of paroxysmal
EEG findings on task performance, but did not indicate a relationship. A non-significant
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relationship between cognition and abnormal EEG findings has also been demonstrated
elsewhere [137, 138]. In contrast, JME patients with at-rest epileptiform discharges (n=11) [142]
have been shown to demonstrate worse abstract reasoning concept formation, and mental
flexibility.
In addition to demonstrating divergence and convergence amongst clinic groups and anatomy
considerations, the genetic involvement of JME may also elucidate predictable patterns of
cognitive performance. In a unique approach to demonstrating potential genetic vulnerabili‐
ties that underlie cognitive performance, there is evidence [131] that first degree relatives of
JME patients have lower performance on tasks of sustained attention than relatives of indi‐
viduals diagnosed with CAE or TLE. Another small sample of young adults with JME
performed similarly to their siblings on a number of tasks related to executive, language, verbal
memory, phonemic and semantic fluency, and general intellectual functioning [144]. However,
the JME group scored in a range suggesting more self-reported symptoms related to behav‐
ioral, motivational, cognitive, and emotional factors than their sibling [144]. Somnez et al. [143]
also reported a number of similarities in cognitive performance for patients with JME who had
a relative with epilepsy and those who did not have a relative with epilepsy. Nevertheless, the
authors indicated that patients with a family history of seizures were found to be “less
successful in general cognitive evaluation,” in particular on a spatial perceptual task, forward
auditory digit span repetition, and speeded reading measure. A more recent sibling study of
cognitive differences in JME patients [136] included data indicating that a group of siblings
showed no significant differences on any cognitive measure when compared with the JME
group. Moreover, the siblings’ performance was not discrepant from a group of healthy
controls except for an aspect that indicates JME participants generated more responses that
were counter to the test rules on a measure of prospective memory (i.e., remembering to
remember). Taken together, findings in these studies may reflect a familial genetic vulnera‐
bility for subtle cognitive abnormalities in JME family members who do not have a history of
seizures.
In general, the aggregate of cognitive studies in JME patients has indicated that JME patients
do not typically perform at the same level as individuals from control or normative groups.
Moreover, review of the literature suggests that more studies show JME patients have poorer
performance on frontally mediated tasks (i.e., processing speed, response inhibition, and
verbal fluency) Than those that do not show such difference. So, too, virtually no study has
shown that JME groups perform better than controls on any number of tasks. However, the
totality of results has not been consistent and a number of studies have shown that patients
with JME sometimes display cognitive abnormalities in other neuropsychological domains as
well. Additionally, the literature is weighted toward including mainly tasks related to frontal
lobe functioning at the expense of investigating other cognitive domains, which results in
literature bias. There are also conflicting data across the studies comparing controls with JME
patients to the degree that it is difficult to definitively conclude there is a specific JME cognitive
endophenotype, such as a “frontal syndrome.” It is likely that, based on the number of
inconsistent results for both fontal and non-frontal task performances, any given JME patient
may display a range of cognitive abnormalities-the expression of which is likely dependent
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upon various factors that have not been adequately described in the literature. As such, it will
be important for researchers to continue to investigate etiological contributors to cognitive
functioning in JME patients that account for the influence of psychosocial variables, neuro‐
biological functions, and various other metrics of individual differences and disease charac‐
teristics.
15. Psychiatric complications
Psychiatric disorders are common in the general population [153] and the presence of a
neurological disorder has been associated with increased prevalence [154]. Patients with
epilepsy, as a group, have a high rate of psychopathology [155] and present with unique
psychiatric problems that may complicate proper diagnosis and treatment. For instance,
patients with epilepsy may experience psychiatric symptoms that are caused by, maintained,
or exacerbated by discrete epileptiform activity. The most striking incidence of this relates to
peri-ictal states that cause intense psychiatric reactions that include any number of symptoms
consistent with anxiety, fear and panic, negative emotionality, and even psychotic phenomena
[156]. Moreover, psychiatric factors in epilepsy have been related to challenges that stem from
the functional impact of the disease that serve to restrict, modify, or impair individuals’
functional status [157]. In that regard, limitations, such as restricted job duties and driving
cessation, have been related to a higher incidence of mental health and psychological adjust‐
ment challenges along with lower rated quality of life [158].
While much is known about the psychosocial aspects of some common epilepsy syndromes
(i.e., TLE), there has been less prominent study in individuals who have been diagnosed with
other less frequently occurring forms of epilepsy. Within the JME literature, there are oft
mentioned assertions that individuals with JME possess characteristics including irresponsi‐
bility, labile behavior, poor discipline, quixotic temperaments, emotional regulation difficul‐
ties, and egocentrism, although few empirical data have directly addressed these psychological
traits in a systematic fashion [159]. Early retrospective study identified that there was a high
portion (36.4%) of “character neurosis disorder” in JME patients [160]. Other indications [161]
were that approximately 29% had some type of psychiatric disorder. Applying personality
typologies that are specific to epilepsy patients has proven challenging [162], although
research-driven examinations have begun to more clearly identify the types of interictal
psychiatric complications that frequently occur in patients with JME. Within that empirical
approach, researchers have reported that a combination of personality features, psychiatric
symptoms, and contemporary psychiatric disorders occur in JME patients. To a lesser extent,
relationships with extra-disease factors, such as social functioning have also been investigated
in JME patients.
In terms of research approaches, differential prevalence designs have shown that JME patients
have a higher rate of psychiatric diagnoses than controls. Standardized diagnostic interviews,
such as the Structured Clinical Interview for DSM-IV [163], have demonstrated rates of
psychopathology in JME patient clinical samples ranging from 35 to 62% [164-167]. Lifetime
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prevalence of Axis I (30%) and Axis II (26%) diagnoses has also been reported to be high, and
a number (47%) have current or lifetime prevalence of some type of disorder. Concerning
specific disorders in studies where standardized diagnostic interviews were used, results are
as follows: anxiety disorders (21-23.8%) [165, 167], generalized anxiety disorder (19-23%) [165,
166, 168], depression (17-20.9%) [165-168], and somatoform disorders (5.6-7%) [165, 166, 168].
Those studies also indicated that less than 5% of patients have a substance abuse disorder,
psychotic disorder, obsessive compulsive disorder, dysthymia, specific phobias, or attention
deficit disorder [165-168]. Beyond Axis I disorders, it has been noted that 9 to 20% of samples
have met criteria for a personality disorder according to structured diagnostic interview [166,
167]. Histrionic, paranoid personality, and borderline personality disorders were most
prevalent. There has been a high rate of Axis I (11.3-19%) [164, 165] and Axis II (23%) [164]
psychiatric comorbidity in those patients who have one diagnosis as well.
Across other various diagnostic schemes, such as retrospective chart review and clinical
judgment, prevalence of any mental disorder varies from 26.5 to 34% [109, 169, 170]. Different
researchers have also reported various combinations of mental disorders in samples such that
25.3% in one study were determined to have either an anxiety, phobia, or somatization disorder
and 18.1% had a mood disorder [140]. Frequency of specific diagnoses for depression
(8.6-14.5%) [109, 170] and anxiety disorders 15.5% [109] have also been reported. Similar to
studies using structured diagnostic interviews, other designs have indicated a low prevalence
(<5%) for psychotic disorders [169] and obsessive compulsive disorder [109, 169]. However,
some data points have been outliers in that less than 5% of samples have been diagnosed with
depression and anxiety disorders as well as depression [169]. In addition to diagnostic rates,
patients with JME have scored significantly higher than controls on measures of symptoms
related to depression, anxiety [171], internalization (24%), and externalization (16%) [172].
Prevalence of personality disorders in studies with less controlled diagnostic procedures have
varied widely and have comprised 3 to 14% of samples [109, 169, 170]. Data from the afore‐
mentioned studies have indicated that groups of patients with JME have a higher incidence of
mental disorders than members of control groups. Such studies have tended not to report
comorbidity rates.
In addition to comparing control groups, research has been conducted examining differential
prevalence of mental health problems in JME groups with that found in other groups of
epilepsy patients. In a study of 157 patients with GGE [173], there were no significant differ‐
ences in rates of psychiatric diagnoses between JME patients (23%) and diagnoses occurring
in other GGE syndromes. In comparison to patients with partial epilepsies, varying degrees
of concordance have been noted. In larger samples [168], similar numbers of psychiatric
disorders have been found in JME patients (49%) and patients with refractory MTS (50%). In
contrast, an early study using a structured diagnostic interview [174] found only 22% of the
JME patients met criteria for a mental disorder, while 55% of patients with TLE met criteria
for a mood disorder. Comparison of prevalence has suggested that JME patients have a lower
rate of psychotic disorders than patients with MTS, although anxiety disorder may be more
prevalent in JME groups (23%). That research group [165] also compared a larger cohort and
did not find differing levels of psychiatric diagnoses (i.e., mood, anxiety or somatoform)
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between JME patients and those with MTS, although the presence of psychotic disorders was
associated with MTS group membership. Indeed, that group also published data [175] from
the same sample that indicated significantly more MTS patients (11.6%) had at least two core
symptoms of psychosis compared with 4.8% of those with JME. However, the proportion of
individuals with post-ictal psychosis or interictal psychosis was similar between the groups.
With regard to symptom severity, a sample of 20 JME and 20 TLE patients had scores on
measures of stress and depression [176] that were similar.
Further research on various broad spectrum measures of personality traits [172] has revealed
a number of disparate findings. Study on JME patients’ responses on metrics of personality
characteristics has indicated JME patients [172] experience significantly higher levels of a
“repressive defensiveness” trait than the test normative sample, although a number of other
variables were not significantly elevated. Other research [177] has compared responses of JME
patients and controls on the Minnesota Multiphasic Personality Inventory [178], and another
group [176] did not find group differences on a Five Factor personality inventory in JME and
TLE patients. Another study [171] of personality features in JME explored possible endophe‐
notypic expressions of personality features that are not part of contemporary psychiatric
diagnostic categorization. As such, compared with controls, JME patients were shown to have
a high rate of novelty seeking, low rate of harm avoidance, and low rate of self-directedness
(e.g., lack of goal direction and incongruent habits). Taken together, these disparate and non-
significant findings have led to conclusions that there may not be a specific personality profile
associated with JME [172, 176].
Finding factors that influence or modify the expression of mental health problems in JME has
also proven elusive. In a retrospective chart review [169] of 155 JME patients, it was shown
that psychiatric disorders were more prevalent in patients with medically resistant seizures
(58.3%) as opposed to non-resistant (19%). Similarly, anxiety disorders in JME patients have
been associated with lack of seizure control and a history of having several lifetime GTCSs
[167]. Moreover, other psychiatric and personality disorders have been associated with seizure
frequency [166]. In contrast, others have not found associations of frequency of psychiatric
diagnoses with duration of epilepsy [164, 168], type of seizures [164, 168], seizure frequency
[164, 168], or number and type of AEDs [168]. Researchers [164] have also not found factors
associated with psychiatric comorbidity including age and medication adherence.
Regarding personality features [177], patient endorsements on measures of personality have
not been related to age of epilepsy, diagnosis onset, or seizure frequency. In JME patients
with a personality disorder compared with JME patients without a personality disorder,
there  have  been  no  group  associations  with  disease  duration  [166],  age  of  onset,  or
“adequate  treatment” [179-181].  However,  there  have  been significant  associations  of
personality facets,  such as  novelty seeking,  with early age of  epilepsy onset  and higher
frequency of myoclonic seizures [171]. Disease chronicity has also been shown to relate to
personality features, such as restraint [172].
In contrast to describing risk factors, researchers have identified potentially protective factors
against anxiety and personality disorders that include being treated with an AED for more
than 2 years [166, 168]. Although the direction of causality for this association is not known, it
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is likely that lower psychological stress promotes adherence, and the effect of being adherent
leads to better seizure control, which also likely results in better psychosocial functioning and
fewer psychiatric symptoms. As psychological stress has been inconsistently shown to be
related with seizure control, researchers have implemented psychological interventions
expecting this will affect seizure outcome. In one such study [109], 58 JME patients with
uncontrolled seizures receiving a “rational AED regimen” participated in psychological
intervention with the goal to eliminate seizure precipitants. Treatment modalities in that study
included an anti-stress program or Cognitive Behavioral Therapy intervention. The results
from that study indicated that patients showed a reduction of seizure activity across three time
epochs as treatment progressed and this also coincided with ratings of psychiatric functioning.
This is particularly relevant as there are indications that psychological factors might relate to
seizure control and perceptions of seizure control. For instance, in a survey of JME patients,
62 of 75 respondents (83%) reported that they viewed stress as the most frequent seizure
precipitant [35]. These findings provide preliminary evidence that medication adherence and
psychological treatment may have important roles in influencing emotional well-being in these
patients.
Along with rates of psychiatric problems, other functional outcomes have been examined. For
example, long-term follow-up of JME patients [14] has indicated that 65% to 77% of patients
reported being “very satisfied” with their health, work, friendships, and social life. However,
61% were prescribed a psychiatric medication, nearly one third were unemployed, and 74%
reported at least one “unfavorable” social outcome (i.e., school suspensions, truancy, fighting,
criminal offense, social isolation, social impulsiveness, unplanned pregnancy). The authors
noted that such outcomes occur at similar rates as other childhood onset epilepsies. Likewise,
other data has indicated that only 22.9% of patients may find employment [140]. JME patients
[182] also have adjustment challenges in work and family life. De Araujo Filho et al. [166] noted
that JME patients, compared with controls, also had a lower DSM-IV Global Assessment of
Functioning score and they reported a higher number of psychosocial problems.
As neurobiological theories of psychiatric disorders continue to be advanced [183, 184], there
have also been more studies of cerebral functioning in patients with epilepsy and comorbid
psychiatric conditions [185]. In that vein, a group from Brazil has been at the forefront of
examining characteristics of brain structure and function in JME patients with and without
psychiatric diagnoses. In particular, they [180] have shown small to medium correlations for
NAA/Cr in the left medial primary motor region and right thalamus, and small to medium
correlations for GLX/Cr in the right medial primary motor and left lateral primary motor areas
for psychiatric JME patients. That group [179] also showed that 16 JME patients with a cluster
B personality disorder had reduction of GMV in right thalamus compared with JME patients
with no psychiatric problems. The JME group with personality disorders also had bilateral
increases in GMV in the middle frontal gyrus and right orbitofrontal cortex, and decreased
white matter in the posterior corpus callosum. Additional study [181] of cluster B personality
disorders in patients with JME showed bilateral morphological changes in thalamic, frontal,
and limbic structures compared with JME patients with no psychiatric disorder.
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Overall, the current data do not consistently support a specific combination of behavioral or
psychiatric symptoms among JME patients suggestive of a personality syndrome. In general,
rates of psychiatric diagnoses in JME patients have been shown to be higher than the general
population. Further, preliminary data suggest that JME patients have a higher rate of anxiety
symptoms and less prevalence of psychotic symptoms compared with TLE patients. However,
while there are a number of studies of psychiatric functioning in other epilepsies, such as TLE,
psychiatric data in JME patients remain inadequate. Moreover, a number of studies typically
lack satisfactory sample size, control and differing patients groups, psychosocial contributors,
neuroimaging (i.e., structural and functional) studies, or neurophysiological metrics. Addi‐
tionally, there is an absence in the literature regarding genetic, sibling, or family studies that
address psychiatric variables. Such data will further help advance causal models of psycho‐
pathology and influence treatment implications. Although many details regarding psychiatric
problems in JME are not well defined, the combined data has immediate implications for
clinical care.
16. Pathophysiology
Based upon evidence of broad cognitive dysfunction and psychiatric problems along with the
findings that there are various seizures triggers and EEG findings, mounting evidence has
suggested that JME affects the brain in a generalized manner. Nonetheless, the contention that
JME is a disease of the frontal lobe and or thalamus has been asserted consistently by the
literature, even in the face of contradictory neuroimaging and neuropsychological findings.
Recent developments in genetics and neuroimaging have opened new avenues to understand
the mechanisms underlying GGEs and expand the conceptualization of JME.
Genetics: The genetic inheritance of JME is complex as about 20 chromosomal loci have been
linked to the disease. While several channelopathies have been associated with multiple GGE
phenotypes, particular mutations have also been specifically implicated in JME. For instance,
GABRA1 mutation reducing GABA-receptor function and expression [186], and EFHC1
mutations affecting mitotic spindle organization [187, 188], are both candidate mechanisms.
Autosomal dominant inheritance of a GABRA-1 mutation was reported in a large French-
Canadian family with seven members exhibiting JME [186]. GABRA1 on chromosome 5q34
encodes for the α1-subunit of the γ-aminobutyric acid receptor subtype A (GABAA-receptor),
linked to a chloride-ionophore. Activation of this receptor allows chloride to enter the neuron,
leading to hyperpolarization. The GABRA1 mutation leads to a loss of function of the GABAA-
receptor in vitro, either due to altered gating properties or decreased expression of receptors
at the cell surface, resulting in decreased inhibition.
EFHC1 is located on chromosome 6p11 and was the first gene to be identified with specific
linkage to JME [58]. EHFC1 mutations are more commonly associated with JME than channe‐
lopathies, accounting for 9% of JME cases [189]. They are inherited in an autosomal dominant
fashion, but also account for singletons and sporadic cases. The putative role of EFHC1 is
evolving, but appears to affect neuronal division and migration during corticogenesis [187,
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190]. EFHC1 was originally shown to be a microtubule–associated protein (MAP), localized to
the centrosome and the mitotic spindle. Loss of function of EFHC1 disrupts mitotic spindle
organization and impairs radial migration of neurons to the developing cortex. Moreover,
recent evidence points to impaired radial glia scaffold formation and altered morphology of
both radially (mainly excitatory) and tangentially (mainly inhibitory) migrating neurons. This
disruption of migration results in fewer neurons and impaired cortical migration of both
excitatory and inhibitory neurons. Impaired morphology, i.e., the inability to transform from
multipolar to bipolar cells, leads to the neurons remaining in the intermediate zone.
Susceptibility genes may also play an important role in the expression of epilepsy phenotypes.
Although channelopathies only account for 3% of JME [187], their genetic associations with
epilepsy are likely important markers for disease characteristics. GABRA2 mutations, in
addition to SCN1A and SCN1B mutations, have been liked to pedigrees with generalized
epilepsy with febrile seizures, whose members may present with many types of epilepsy
syndromes, including JME [186].
There are also several susceptibility single-nucleotide polymorphism (SNP) loci that contribute
to the risk of developing GGE and JME, which has been suggested by genome-wide association
analyses. For GGE, in general, at least three candidate genes have been noted: 1) VRK (2p16.1):
a loci that may affect cortical development, 2) SCNA1 (2q24.3): a loci for coding the α-subunit
of the neuronal voltage-gated sodium channel, mutations of which are the most common cause
of channelopathy-related epilepsy, and 3) PNPO (17q21.32): a loci that is involved in pyridox‐
ine oxidation to an active-cofactor involved in neurotransmitter metabolism. Susceptibility
candidates for specific GGE syndromes, such as absence epilepsy or JME, were also identified.
The linkage associated with JME is at 1q43, flanked by two regions with high recombination
rates and covering the CHRM3 gene, which codes for the M3 muscarinic acetylcholine receptor.
While nicotinic acetylcholine receptor mutations have been linked to autosomal dominant
frontal lobe epilepsy, it is not clear how muscarinic receptors contribute to epileptogenesis.
In summary, the genetic effects of JME are manifold and various genotypes can result in the
same epilepsy syndrome. This may be due to a combination of factors, including the lack of
accurate epilepsy syndrome differences in subphenotypes or failure to identify epigenetic
mechanisms.
Pathology: Brain pathology studies in cases of JME are rare (i.e., approximately 20 cases) as
patients usually have an average life expectancy. Meencke and Janz [191] published brain
pathology in eight patients with GGE, most of whom had myoclonic seizures. They found
microdysgenesis in seven patients, defined as persistent uni-or bipolar cells in the subpial
region, increased cell density in the stratum moleculare, portrusions of neurons against the
pial membrane, containing well-differentiated neurons, columnar neuronal architecture, and
increased neurons in the subcortical white matter. Atypical neurons were also found in the
hippocampus and cerebellum [192]. There was no evidence of gliosis or chronic neuronal loss.
Those findings were criticized for a lack of control group pathology samples [193], and the
authors [191] published an additional number of brains from a mixed group of GGE. Using
that latter group of specimens, the authors reported that there was a frontal-to-parietal
decrease of “microdysplasia”, which was absent in the occipital lobes. In 2000, another group
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compared five GGE patients, who died of SUDEP, to a nonepileptic control group [194]. This
study did not find an increase of the “microdysplasia”. Based upon the small numbers of
patients with heterogeneous electroclinical features and syndromal diagnoses, it is difficult to
draw any conclusions regarding pathology findings that are specific to JME.
Neuroimaging: In contrast to pathology studies, a number of morphometric imaging ap‐
proaches since the 1990s have contributed to the neurobiological understanding of GGE and
JME. Such studies have demonstrated differences between JME patients and normal controls,
and suggest that there are subtle pathological changes difficult to assess by routine histology.
Further, while JME manifests as generalized electroclinical activity, structural imaging has
indicated circumscribed, multiregional abnormalities. Similarly, functional imaging studies
have also demonstrated a predominance of symmetrical multiregional involvement (i.e.,
cerebral blood flow [CBF] or blood oxygen level dependent [BOLD] changes) prior to and
during absence seizures or prolonged spike-and-wave discharges.
Structural Neuroimaging: Routine clinical structural imaging scans, whether computerized
tomography (CT) or magnetic resonance imaging (MRI), are considered normal in individuals
with JME. In contrast, more sensitive techniques, such as voxel-based morphometry (VBM),
can show subtle variations in gray matter concentration or volume that differ in JME patients
compared with healthy controls. An early quantitative MRI volumetric study in GGE partici‐
pants showed increases in normalized gray matter volume (GMV) compared to healthy
controls, but also possible differences between other epilepsy syndromes as well [195]. In a
subsequent VBM study, statistical parametric mapping demonstrated increased mesial frontal
GMV in JME patients. Individual patients also demonstrated additional changes in parieto‐
temporal regions along with decreases frontally in individual patients analyzed by a volume
of interest method [195].
More recent VBM studies in JME patients have demonstrated multiregional volumetric and
morphometric brain changes [196, 197]. Lin et al. [196] showed increased right frontal GMV
and but reduced bilateral thalami, insula, and cerebellar hemisphere volume. Differences in
GMV as a function of photosensitivity were also detected, as there were decreases in occipital
lobe, left inferior frontal lobe, and hippocampal GMV in photosensitive patients compared
with non-photosensitive JME patients. Altered cortical morphology differences in terms of
surface area metrics, and not cortical thickness, was noted in the left hemisphere: insula,
cingulate, occipital pole, middle temporal, and fusiform gyri [197]. Similar differences were
also noted in the right hemisphere: insula, inferior temporal gyrus, and precuneus. Mean
cortical curvature measurements in JME patients were also different from controls in the
bilateral insula, left cingulate, and right inferior temporal gyrus.
Diffusion tensor imaging (DTI) provides a complementary approach to traditional morpho‐
metric and volumetric analyses, as it accounts for white matter connectivity in cortical and
subcortical regions. The most important parameters assessed by DTI are fractional anisotropy
(FA) and mean diffusivity (MD), which provide information about the microstructural
integrity of the white matter pathways. In particular, FA is influenced by myelin integrity and
fiber density, whereas MD is correlated with microscopic membrane disruption and extracel‐
lular fluid accumulation.
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It has been shown that JME patients have symmetric FA reductions in the bilateral superior
and anterior corona radiata, genu and body of the corpus callosum, along and with middle
and superior frontal tracts [139]. White matter tract MD increases coincided with the FA
reduction, although the left superior parietal lobe was also affected. There were no increases
in FA or decreases in MD found in JME patients. Frequency of GTCS was correlated with the
severity of the microstructural changes.
Several studies have shown similar reductions of FA [141] and increases in MD [198], mainly
concentrated in thalamocortical pathways and the corpus callosum; pathways that are
responsible for propagation and synchronization of spike-and-wave discharges. These DTI
changes have been correlated with GMV reduction in the supplementary motor area (SMA)
and posterior cingulate cortices. The SMA FA was correlated with deficits for word naming
tasks and expression, while the posterior cingulate changes predicted cognitive inhibition
scores [141] and deficits in frontal lobe executive motor functioning. A subsequent study by
the same group demonstrated a correlation between DTI and fMRI-based measures of
structural and functional connectivity between prefrontal cognitive cortex and motor cortices
[198]. Connectivity was decreased between prefrontal and frontopolar regions and increased
between occipital cortex and SMA. The authors suggested that the frontal connectivity changes
may be related to cognitive deficits seen in JME, and occipitomotor connectivity may be related
to photosensitivity, although association with these clinical phenotypes were not investigated.
The neuroanatomic basis of GMV and DTI changes is not clear. It is suspected that the
decreased connectivity may be due to altered cortical organization, but as many of these
changes are correlated with disease activity, degenerative changes cannot be ruled out. So far,
the studies have shown disparate findings, thus, leading to an inconclusive picture of cerebral
differences in JME. However, the aggregate of study results suggests diffuse abnormalities
with morphological changes that include regions beyond the frontal lobes. Moreover, patho‐
logical studies are needed to confirm changes in cortical organization and connectivity. To
improve on this knowledge base, an animal model of JME could be utilized to investigate a
number of clinicopathological data points including morphometric changes and histopatho‐
logic findings.
Functional – Interictal PET, MRS, EEG-fMRI: Interictal PET studies using flourodeoxyglucose
(FDG) evaluate metabolism over a 40-minute uptake time. While FDG-PET is not ideal for
evaluating transient ictal state or interictal discharges it does evaluate a more chronic func‐
tional status. In an early study, Swartz et al. [125] indicated that JME patients showed decreased
metabolism in the prefrontal and premotor cortices, which was associated with behavioral and
cognitive dysfunction. Increased metabolism in the bilateral thalami was correlated with
increased ictal or interictal epileptic discharges in another study of JME patients [199]. These
studies demonstrated predominantly frontal lobe dysfunction, and an obvious activation of
the thalami by ictal and interictal epileptic discharges. The absence of cortical activations
suggests more fluctuation in metabolism due to epileptic discharges, decreased neuronal
activity in the interictal state, or a general decrease of metabolism due to the disruptive effect
of epileptic discharges on cognitive activity.
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Magnetic resonance spectroscopy (MRS) can be used to measure neuronal function and
concentrations of neurotransmitters in the cerebral cortex and subcortical structures. One
study showed reduced N-acetyl aspartate (NAA) in the medial frontal lobes (and not in the
occipital lobes) of individuals with JME [200]. The same group [152] showed NAA reduction
was specific to JME as compared to individuals diagnosed with GTCS upon Awakening, but
was similar to patients with CAE and JAE, [201]. However, investigation of cortical regions
was limited and did not involve the lateral frontal, sensorimotor, or parietal areas.
Functional connectivity is a novel method evaluating regional covariance of BOLD signal over
time. Most of the functional connectivity data is derived from generalized spike-and-wave
discharges in individuals with absence epilepsy. Such studies have examined BOLD changes
before, during, and after spike-and-wave discharges. While the thalamocortical networks
projecting mainly to the medial frontal lobe are briefly activated during these discharges, more
sustained activations occur in the parietal lobes prior to the discharges. As the discharges
evolve, increases in BOLD dissipate, resulting in decreased frontoparietal BOLD signal. The
brief discharges associated with JME are less likely to cause similar degrees of BOLD changes.
Therefore, evaluating more stable measures such as functional connectivity, can provide more
information regarding the networks.
One group has contributed greatly to evaluating connectivity both structurally and function‐
ally in individuals with JME [141, 198]. As mentioned above, they have demonstrated that
functional connectivity is closely correlated with structural connectivity in the medial frontal
cortices in individuals with JME [198]. They showed that during verbal fluency tasks, there is
diffuse symmetrical activation of the SMA, bilateral inferior frontal gyri, left premotor area,
left thalamus and bilateral putamen, as well as bilateral ventral visual areas. The thalamic
region, showing altered connectivity on DTI, was connected to cortices largely overlapping
the areas of functional activation. Overall, the individuals with JME showed increased task-
dependent connectivity with respect to the frontal cortices compared to controls. Based upon
these findings, the authors concluded that the thalamus serves an important function in
increased frontal connectivity and coherence.
However, another study of functional connectivity in GGE, which included a large number of
patients with JME, showed that there was no alteration of thalamic or mesial frontal connec‐
tivity when no discharges occurred [202]. Although the investigative techniques have differed
between studies and selection biases may be present, the latter study suggests that generalized
spike-and-wave discharges may be generated by healthy networks in response to abnormal
connectivity and cortical synchronization in disparate brain regions. Indeed, another study
showed alterations in default mode network (DMN) connectivity (in the absence of ictal or
interictal epileptic discharges) between posterior and anterior nodes in patients with GGE
[203]. Given the current limitations, additional methods, such as intracranial electrophysio‐
logical recordings and subsequent pathological examination would help elucidate the
mechanisms underlying the CBF changes.
Transcranial Magnetic Stimulation: Transcranial magnetic stimulation (TMS) leads to a brief
depolarization of cortical neurons, and can target brain regions such as the motor and language
cortices. Motor cortex stimulation, such as the primary hand motor area, is conducted
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frequently as the stimulus direction and intensity can be optimized to specifically activate hand
muscles. TMS can be applied using single or paired pulses. Single pulse TMS is used to measure
the resting motor threshold and the cortical silent period (CSP). Furthermore, the paired pulse
stimulation paradigm is used measure short-latency intracortical inhibition and facilitation.
Early studies demonstrated an increase in CSP in individuals with GGE, suggesting increased
intracortical inhibition [204]. Sleep deprivation in individuals with GGE resulted in a greater
change in cortical excitability compared to patients with partial epilepsies or controls, based
upon paired-pulse studies [205]. ILS appears to decrease CSP in healthy controls, but not in
photosensitive or nonphotosensitive individuals with GGE [206]. These findings are somewhat
counterintuitive, as it would be expected that hyperexcitability would be observed in the motor
cortices of GGE patients.
Antiepileptic medications can reduce cortical excitability, but there also seems to be variable
findings across studies of various GGE syndromes and stimulation protocols. A meta-analysis,
showed normal rMT threshold in all GGE patients, except for individuals with JME, who had
decreased motor thresholds compared to healthy controls [207], suggesting a degree of cortical
excitability in the patients. In a subsequent study, the same group showed that rMT was
decreased for photosensitive individuals with GGE compared to those without, although this
may be due to syndrome-specific bias, as photosensitivity is most commonly associated with
JME [208].
Animal Models: Due to its high rate of photosensitivity, the bamboo species, Papio hamadryas
papio, has long been investigated as a model for epileptic photosensitivity [209]. Researchers
established the electrophysiological mechanisms of the model by intracranial depth electrode
recordings during photoepileptic responses that occurred with or without lesioned pathways.
The ictal and interictal epileptic discharges have been shown to conform to a generalized
cerebral distribution, and photic stimulation in the baboons elicits both myoclonic seizures
and GTCS. Unlike humans, who respond to ILS at different frequencies (i.e., 12-18Hz), this
species is maximally photosensitive at frequencies of 20-25 Hz. However, like humans, they
are the most sensitivity to seizure activity in mornings, shortly after awakening. In order to
study the seizures in a controlled way, researchers typically elicit activation by ILS, often after
pretreatment with allylglycine, a GABA synthesis inhibitor, or by administering proconvul‐
sants (e.g., pentylenetetrazol) [210].
Observations of the baboon’s photoparoxysmal responses have indicated that there are
generalized spike-and-wave complexes that occur maximally in the frontocentral regions,
particularly in the mesial frontal surfaces [43]. During ILS, the occipital driving responses
remain localized to occipito-parietal areas with occipital IEDs being rare and temporally
unsustained. Fischer-Williams’s et al. [43] early study showed that subcortical structures,
thalamus, basal ganglia, and brainstem were only secondarily affected by frontocentral IEDs,
usually in association with high-amplitude or repetitive discharges. The amygdala, hippo‐
campus, and uncus were not involved in the photoepileptic responses.
In addition, paroxysmal visually evoked potential (PVEP) studies, using single flash stimuli
administered after a 10 second train of 25 Hz ILS, have enabled researchers to track discrete
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electrophysiological events through cortical-subcortical networks. In one study, earliest
activation of frontocentral IEDs occurred 20 to 30 milliseconds after the flash, with a subse‐
quent eyelid or facial myoclonus occurring 10 to 12 milliseconds later [211]. Motor symptoms
tend to occur only when the amplitude of the cortical discharges exceeded 200 microvolts [212].
Following a PVEP, activation of thalamic nuclei (e.g., ventralis lateralis, centrum medianum,
& lateralis posterior) occurs at cortical discharge amplitudes exceeding 400 microvolts. Silva-
Barrat et al. [213] also demonstrated that photosensitive and asymptomatic control baboons
show difference PVEP responses in peristriate and parietal regions, but not in the striate or
cortical responses. It was also shown that frontocentral ictal or interictal epileptic discharges
were not activated by ILS following bilateral occipital lobe ablation, while destruction of the
superior colliculus or pulvinar unilaterally caused only transient suppression of photoepileptic
responses [214]. In terms of other lesion study, corpus callosum sectioning in combination with
unilateral stimulation of the occipital lobe resulted in frontocentral discharges and seizures
that remained ipsilateral to the activated occipital lobe [215].
Although the epilepsy in these baboons appears similar to JME in many ways, early researchers
failed to establish a model for JME from characteristics seen with the baboons. However, the
phenotypic expression of several hundred baboons has recently been described clinically and
with scalp EEG [216]. The onset of the syndrome typically occurs in adolescence, there is a
preponderance of myoclonic and GTCS, and there is a similar diurnal pattern (i.e., predomi‐
nately in the morning) to JME [217]. The myoclonic seizures tend to affect the face and arms.
The GTCS tend to occur in a sporadic fashion, and can be triggered by handling or ketamine.
The interictal epileptic discharges are generalized in distribution with 4-6 Hz in frequency,
although 2-3 Hz discharges have been noted in younger baboons [218]. Younger baboons can
also present with absence seizures, and even spike-and-wave stupor [216]. Although the
baboon model of epilepsy and JME share many clinical characteristics, including a genetic
etiology, the mode of inheritance and underlying genotypes are not known.
Szabó et al. [219, 220] have also evaluated structural and functional neuroimaging in a large
baboon colony. Their findings indicated that while routine structural MRI studies are normal,
morphometric analyses revealed decreased central and intraparietal sulci along with cingulate
sulci in baboons that showed IEDs [221]. The smaller sulcal areas may reflect an underlying
developmental anomaly, resulting in decreased U-fibers, rather than a process due to aging or
degenerative disease.
Functional studies have aimed to describe epileptic neuronal networks. IED rate and associ‐
ated cerebral blood flow changes on H215O-PET have demonstrated co-activations of the
premotor, perirolandic, insular-parietal, and occipital cortices, areas that are also observed in
human GGE networks [222]. Resting state fMRI has shown altered connectivity of the motor,
but not the visual cortices, and DMN connectivity was altered in the epileptic baboons as well
[223]. This group has also used intracranial video-EEG in combination with depth, grid, and
strip electrodes in order to improve spatial resolution [224]. Results from this approach
indicated that frequent multiregional IEDs occur, which appears to trigger generalized
discharges. The researchers also recorded myoclonic and GTCS, most of which were triggered
multifocally. The focal regions that were most active, according to invasive monitoring,
Epilepsy Topics108
included the parieto-occipital region, parietal lobe, premotor area, and orbitofrontal cortex.
This was unexpected as the scalp EEG demonstrated only generalized discharges, and the
multifocal discharges appeared to occur both parietally and frontally, reflecting a more diffuse
pathology.
Previous examinations of pathology have not shown cortical abnormalities in these animals,
suggesting developmental changes or seizure-induced injury [225]. Comparison of neuronal
counts from the molecular layer, cortical layer 6 and subcortically, in three sulci, namely the
cingulate, intraparietal, and lunate sulcus between asymptomatic photosensitive and healthy
control baboons did not demonstrate cortical neuronal reductions, but did detect increased
numbers of neurons in the subcortical white matter of the anterior cingulate sulcus [226].
Neuronal flow cytometry, on the other hand, demonstrated cortical neuronal reductions,
particularly in the frontal regions related to motor functions and somatosensory cortex [227].
The motor cortices most involved were the face and hand regions, areas most commonly
involved in the manifestation of myoclonic seizures. The decreased cell counts are likely to
result in decreased functional connectivity, especially in the motor cortices. The electrophy‐
siological effects of the neuron reductions are unclear, but may be related to the extent that
inhibitory and excitatory neurons are affected. More detailed pathology for specific types of
neurons needs to be pursued, and a qualitative evaluation of cortical organization also needs
to be considered.
17. Conclusions
JME is a commonly occurring and electroclinically well-defined neurological disease. As with
most GGEs, it is relatively straightforward to diagnose and treat; however, there is still
uncertainty regarding features which may influence a poor response to antiepileptic medica‐
tions and complicate overall prognosis. Compared to other types of GGE, JME appears to have
a structural etiology. Thus, although it shares commonalities with other GGEs, JME breaks
that mold, as the condition has been associated with multiregional and/or asymmetric
electroclinical findings. While the nature and development of that structural and functional
etiology does not appear to be frontal lobe specific, research has yet to define a replicable model
for the disease. Moreover, as JME sub-syndromes [228] may have overlapping features with
other epilepsies, establishment of cognitive signs and symptoms that are specific to JME has
continued to elude researchers.
As a result of the apparent time-course of syndrome onset along with differing prevalence and
prognosis across the lifespan, in conjunction with the subtle cerebral abnormalities as noted
above, some cases of JME likely reflect a set of underlying neurodevelopmental processes.
Nevertheless, there remains a lack of knowledge regarding histopathology, electroclinicial
characteristics and propagation patterns, genetic contributors to phenotypic expression, and
disease biomarkers. Given its similarities to human GGE syndromes (i.e., similar seizure types
and electrophysiological characteristics) and methodical constraints in human research, recent
contributions from the animal literature suggest that continued investigation of these factors
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in a baboon population will offer a unique avenue to further refine human models of JME,
particularly in the setting of photosensitivity. Furthermore, pharmacological development
would likely be assisted by employing trials of agents in animals that show behaviors consis‐
tent with human phenotypes.
In terms of treatment, various combinations of agents have been shown effective, although
some cases of JME result in intractability. Overall, regardless of intractability, JME has the
potential for negatively impacting quality of life. For instance, recent studies indicated
discernible interictal effects on cognition and behavior, even in patients that are relatively well-
controlled. Thus, contrary to previous assertions and clinical lore, JME does not appear to be
a “benign” disease.
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